Blood Podcast
265 episodes - English - Latest episode: 11 days ago - ★★★★ - 44 ratingsThe Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Post-vaccination COVID-19 in patients with hematologic malignancies
December 01, 2021 17:30 - 22 minutes - 30.9 MBAll four studies included in this podcast present preliminary data with modest numbers of patients, and therefore, the findings should be interpreted with these limitations. Likewise, the impact of specific strains and waning antibody levels after COVID-19 vaccination will require further follow-up, since the Delta variant was not the dominant strain in circulation at the time of this research. The first two studies assess the immune responses to vaccination in two specific high-risk...
Asciminib versus bosutinib in CML; dopamine signaling and hematopoietic stem cells; complement factor C5 and VTE risk
November 25, 2021 17:30 - 20 minutes - 19.2 MBIn this week’s episode, we’ll learn more about the efficacy of asciminib in patients with chronic myeloid leukemia who are resistant or intolerant to two or more tyrosine kinase inhibitors, discuss the role of dopamine signaling in hematopoietic stem and progenitor cell function, and learn more about elevated plasma concentration of complement factor C5 as a risk factor for venous thromboembolism.
Danicopan add-on therapy in PNH, neural networks to identify bone marrow cells, and RNA editome and hematopoiesis
November 18, 2021 17:30 - 17 minutes - 16.2 MBIn this week’s episode, we’ll review results of a phase 2 study showing the beneficial effects of a first-in-class factor D inhibitor as add-on therapy in PNH patients who remain anemic and are transfusion-dependent despite C5 inhibition. Next, we’ll review the work of researchers who have developed a neural network that they say is highly accurate in differentiating between bone marrow cell morphologies. We’ll close with a report demonstrating that RNA editing of antizyme inhibitor ...
Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause
November 11, 2021 17:30 - 19 minutes - 17.8 MBIn this week’s episode, we’ll learn more about the application of machine learning in molecular subclassification and prognostication of acute myeloid leukemia or AML, discuss the role of aging bone marrow in leukemia progression, and learn more about the challenges in treating bleeding disorders of unknown cause.
Anti-CD36-antibody therapy of neonatal alloimmune thrombocytopenia, costs of hemophilia B gene therapy, and insights into erythroid maturation
November 04, 2021 17:00 - 17 minutes - 16.3 MBIn this week’s episode, we’ll review a research article showing beneficial effects of prenatal immunotherapy in a mouse model of anti-CD36-mediated fetal and neonatal alloimmune thrombocytopenia. Next, we’ll look at results of a simulation analysis suggesting that gene therapy for hemophilia B is more cost-effective than on-demand or prophylactic factor treatment. We’ll conclude with a report which provides important new insights into regulation of terminal erythroid maturation at th...
Genetic risks for CMV after BMT, multiplex gene editing to reactivate HbF, and rewiring plasma cells in light chain amyloidosis and myeloma
October 28, 2021 16:30 - 19 minutes - 17.9 MBIn this week’s episode, we’ll discuss an analysis of genetic risks for CMV infection after an allogeneic hematopoietic stem cell transplant, learn more about a new multiplex gene editing approach to reactivate fetal hemoglobin in thalassemia, and discuss transcriptional rewiring of normal plasma cell development in light-chain amyloidosis and myeloma.
Omidubicel vs standard umbilical cord blood transplant, CAR T-cell associated lymphomas, and CD63 and ferritin export
October 21, 2021 16:30 - 19 minutes - 18.3 MBIn this week’s episode, we’ll review results of a phase 3 randomized study demonstrating shorter time to neutrophil and platelet recovery with an ex vivo expanded hematopoietic progenitor cell product called omidubicel as compared to standard umbilical cord transplantation. Next, we’ll look at preliminary data on the development of lymphomas originating from piggyBac-modified CD19 CAR T-cells, sounding a note of caution for researchers exploring new gene modification methodologies fo...
Iron homeostasis and anemia of inflammation in TB, and long-term outcomes of gene therapy in adenosine deaminase-deficient SCID patients
October 14, 2021 16:30 - 14 minutes - 13.4 MBIn this week’s episode, we will review a study that prospectively followed tuberculosis patients after treatment initiation to evaluate iron handling during the resolution of inflammatory anemia. We will also examine clinical benefit and long-term safety of gamma-retroviral gene therapy in patients with adenosine deaminase deficient severe combined immunodeficiency.
Immune megakaryocytes, PD1 deletions in CTCL, and COVID-19 vaccine and VITT
October 07, 2021 16:30 - 19 minutes - 17.5 MBIn this week’s episode, we’ll review a study providing new insights on megakaryocyte diversity and function, including a unique subpopulation that may act as immune cells. Next, we’ll review research that intriguingly reveals a putative role for the PD1 gene in cutaneous T-cell lymphoma. Lastly, we’ll conclude with a report demonstrating a lack of cross-reaction between the antibodies that cause vaccine-induced thrombocytopenia and thrombosis, and the COVID-19 spike protein.
Inhibition of P-selectin as an anticoagulant, prognostic implications of CEBPA mutations in AML, and treating sickle cell disease with voxelitor
September 30, 2021 17:00 - 15 minutes - 14.2 MBIn this week’s episode, we’ll review a study that demonstrates the efficacy of a synthetic inhibitor termed P-G6 that blocks P-selectin signaling and reduces thrombus formation in a pre-clinical model of non-occlusive venous thrombosis, learn more about how biallelic and single bZip CEBPA mutations have an equally favorable prognostic impact in acute myeloid leukemia, and examine the effects of modifying the pathophysiology of sickle cell anemia with therapeutic agents that increase ...
Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation
September 23, 2021 16:30 - 15 minutes - 14.2 MBIn this week’s episode, we review results of preclinical investigations that sound a note of caution regarding the potential use of JAK inhibitors as treatment for hemophagocytic lymphohistiocytosis (or HLH), research that provides new insights on how CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax, and conclude with a report that demonstrates cooperation between B cell receptor signaling and genetic lesions in CDKN2A, CDKN2B and TP53 in Richter transform...
Improved risk assessment in adult BCR-ABL1-negative B-ALL, value of clone metrics in clonal cytopenias, a placental protease generates a peptide to inhibit NET formation
September 16, 2021 16:30 - 17 minutes - 16.3 MBIn this week’s episode, we will review an integrated analysis of one of the largest adult BCR-ABL1-negative B-ALL patient cohorts treated in a single trial, learn more about the genotypic and phenotypic features of patients with clonal cytopenias, and look at a study showing that a serine protease expressed in the placenta cleaves α1-antitrypsin to generate a fragment that inhibits formation of neutrophil extracellular traps in neonates.
Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS
September 09, 2021 16:30 - 22 minutes - 20.8 MBIn this week’s episode, we’ll review updated results of a phase 1b study that provide strong support for the use of fixed-duration venetoclax in patients with relapsed or refractory CLL. Next, we’ll review a research paper that provides new insights on the different subtypes of invariant natural killer T cells, which appear to have diverse immunoregulatory properties and anti-tumor effects. We will finish up with a report indicating that rare variants in the telomerase gene, TERT, ar...
Activated BCL11B in acute leukemias, SARS-CoV-2 antibody responses in lymphoma patients receiving B-cell therapies, and PD-L1 in neutrophil apoptosis and tissue inflammation
September 02, 2021 16:30 - 17 minutes - 16.5 MBIn this week’s episode, we will review a study that shows that BCL11B is an important oncogene in acute leukemias with myeloid and T-lymphoid features, learn more about antibody responses to SARS-CoV-2 vaccination in lymphoma patients receiving B-cell directed therapies, and examine the role of programmed death ligand 1 (or PD-L1) and the PI 3 kinase-AKT survival pathway in delayed neutrophil apoptosis at sites of tissue inflammation.
Blood Review Series on Mechanisms of Hematologic Malignancies
August 26, 2021 16:30 - 28 minutes - 25.9 MBTo reach the goal of curing currently incurable hematologic malignancies, we need to go beyond focusing on single gene mutations and gain deeper understanding of the consequences of genetic alterations on gene-regulatory pathways. Edited by John Crispino, these 5 cutting-edge reviews from leaders in the their fields not only summarize our current understanding of key pathways that contribute to myeloid malignancies, but also discuss new therapeutic avenues related to them. They provi...
IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia
August 26, 2021 16:30 - 18 minutes - 16.8 MBIn this week's episode, we will review a study that proposes IFN-λ therapy as a novel strategy to boost gut protection in GvHD, examine the immunomodulatory effects of decitabine in ITP, and learn about the discovery of TET2 mutations in chronic natural killer large granular lymphocyte leukemia
Choosing chemotherapy for older patients with AML, the role of the microenvironment in pediatric ALL, and efficacy of thrombopoietin receptor agonists in elderly patients with ITP
August 19, 2021 16:30 - 18 minutes - 16.6 MBIn this week's episode, we will review a report on a clinical prognostic tool that identifies which group of older, fit acute myeloid leukemia patients may derive survival benefit from intensive induction and consolidation chemotherapy, learn more about how pediatric acute myeloid leukemia cells connect with mesenchymal stromal cells and the potential to exploit these cell-cell contacts in AML treatments, and examine the effects of eltrombopag and romiplostim in elderly patients with...
Brentuximab plus nivolumab in refractory/relapsed Hodgkin lymphoma, the signature of aging hematopoietic stem cells, and hepatocyte neogenin in iron homeostasis
August 12, 2021 16:30 - 16 minutes - 15 MBIn this week's episode, we’ll discuss the safety and efficacy of brentuximab vedotin in combination with nivolumab in patients with relapsed and refractory classical Hodgkin lymphoma, learn more about the aging signature of murine hematopoietic stem cells, and discuss the role of hepatocyte neogenin in iron homeostasis.
Latest Research on the Intensity of AML Therapy in Older Patients, Platelets and T cell Activity in Sepsis, and Genotyping for CNS Lymphoma
August 05, 2021 16:30 - 19 minutes - 17.8 MBIn this week's episode, we’ll start by reviewing an intriguing study that, while not randomized, calls into question whether less-intensive induction therapies provide a survival or quality of life benefit in older patients with AML. Next, we will review the somewhat surprising findings from human and mouse model studies demonstrating that platelets downregulate T cell activity during sepsis, a finding that is associated with reduced survival. We will close with a report on a targete...
Vaccine-induced Immune Thrombotic Thrombocytopenia
July 29, 2021 16:30 - 17 minutes - 16.2 MBToday’s episode is a special edition that focuses exclusively on vaccine-induced immune thrombotic thrombocytopenia, or VITT, a rare but potentially fatal syndrome associated with adenovirus-based COVID-19 vaccines. The VITT syndrome is characterized by thrombocytopenia and thrombosis in association with platelet-activating anti-platelet factor 4 antibodies. First, we’ll review an insightful Spotlight article on what is known about VITT to date. Then we’ll discuss two new brief repor...
Latest research in post-transplant cyclophosphamide in matched unrelated versus haploidentical donors, outcomes in patients with AITL, and high molecular weight kininogen in acetaminophen-induced liver injury
July 22, 2021 16:30 - 17 minutes - 16 MBIn this week’s episode, we will learn more about the use of high-dose post-transplant cyclophosphamide in matched unrelated donors versus HLA haploidentical grafts, review prognostic factors and outcomes from the largest cohort of patients with angioimmunoblastic T-cell lymphoma reported to date, and look at a study that suggests that high molecular weight kininogen contributes to acetaminophen-induced liver injury.
Latest research in thrombosis in pediatric COVID-19, prognostic tool for very early stage CLL, and frontline treatment for newly diagnosed myeloma
July 15, 2021 16:30 - 17 minutes - 16.4 MBIn this week's episode, our studies include an analysis of thrombosis in pediatric patients with COVID-19, the predictive value of the CLL-international prognostic index in monoclonal B-cell lymphocytosis and Rai 0 stage CLL, and results from a phase 2 trial in newly diagnosed multiple myeloma patients treated with frontline carfilzomib, lenalidomide, and dexamethasone with autologous stem cell transplant.
Latest Research: Immunity to CMV, lymphoma microenvironment, and tPA induced bleeding
July 08, 2021 16:30 - 14 minutes - 13.6 MBIn this week's episode, we will review a study that addresses the issue of reconstitution of immunity to cytomegalovirus in transplant patients receiving the antiviral drug letermovir, learn more about the role extracellular vesicles play in forming a tumor supportive stromal cell niche in follicular lymphoma, and finally, look at a report identifying a mechanism that couples the treatment of acute ischemic stroke with tissue plasminogen activator to the development of intracerebral ...
VEXAS: A Newly Identified Adult-onset Hemato-inflammatory Syndrome
July 01, 2021 16:30 - 17 minutes - 15.8 MBToday’s podcast is a special edition that focuses exclusively on VEXAS syndrome, a newly identified adult-onset inflammatory syndrome with associated hematologic manifestations. VEXAS syndrome is a poor-prognosis disease caused by somatic mutations in the X-linked gene, UBA1. It was first reported by Beck and colleagues in the New England Journal of Medicine in December 2020.
Season 2, Episode 25
June 24, 2021 16:30 - 18 minutes - 17.2 MBIn this week’s episode, we will review a study that uses a combination of mouse models to identify IL-19 as a potent cytokine capable of promoting expansion and proliferation of neutrophils, examine the effects of targeted therapies on autoimmune cytopenia in patients with chronic lymphocytic leukemia, and learn about the mechanism of excessive complement activation caused by mutations in factor H-related protein 1 in patients with atypical hemolytic uremic syndrome.
Season 2, Episode 24
June 17, 2021 16:30 - 22 minutes - 20.3 MBIn this week’s episode, we will review the role of the hypoxia pathway in regulating neutrophil migration, explore the relationship between endothelial extracellular vesicles and the hemostatic effects of clotting Factor VIIa, and finally look at long-term outcomes with the BTK-inhibitor acalabrutinib in treatment-naive chronic lymphocytic leukemia patients.
Season 2, Bonus: Blood Review Series on Platelets and Cancer
June 10, 2021 17:45 - 35 minutes - 32.5 MBPlatelets are critical for hemostasis and thrombosis, but recent research highlights their role in many other processes, including inflammation, wound healing, and lymphangiogenesis. In this episode, Drs. José López, Elisabeth Battinelli, Craig Williams, and Owen McCarty discuss the review series on platelets and cancer. The series focuses on the emerging role of platelets in cancer, influencing tumor growth and metastasis, immune evasion, and tumor angiogenesis. The reviews present ...
Season 2, Episode 23
June 10, 2021 16:30 - 20 minutes - 18.6 MBIn this week’s episode, we will review a study demonstrating low rates of response to the Pfizer-BioNTech COVID-19 vaccine among patients with chronic lymphocytic leukemia, review a study looking at associations between post-transplantation cyclophosphamide and cytomegalovirus infection according to donor source, and look at new research indicating that abnormal venous calf muscle pump function in the legs is a risk factor for venous thromboembolism (VTE) and predictor of all-cause m...
Season 2, Episode 22
June 03, 2021 16:30 - 18 minutes - 16.8 MBIn this week’s episode, we will review a study in sickle cell disease patients reporting abnormal retention of mitochondria in circulating red cells and elevated mitochondrial DNA in plasma, learn more about the fate of FLT3-ITD clones in AML patients treated with midostaurin, and look at a study showing, for the first time, that selected elderly patients with newly diagnosed multiple myeloma benefit from modification of standard myeloma treatment based on the level of frailty.
Season 2, Episode 21
May 27, 2021 16:30 - 16 minutes - 15.2 MBIn this week’s episode we will review a phase 1 clinical trial looking at novel fully humanized BCMA-targeting CAR in patients with relapsed or refractory multiple myeloma, discuss a plenary paper reporting that different lymph nodes from patients with follicular lymphoma often have distinct clones, and finally, examine a Letter to Blood reporting high levels of markers of complement activation in plasma during quiescent phases in catastrophic antiphospholipid syndrome patients. ...
Season 2, Episode 20
May 20, 2021 16:30 - 20 minutes - 18.5 MBIn this week’s episode, we will examine the prognostic significance of co-mutations in IDH-mutated AML, explore an alternative method of warfarin monitoring, and finally, consider the role of tumor suppressor TP53 in determining response to venetoclax and related agents.
Season 2, Episode 19
May 13, 2021 17:30 - 18 minutes - 17.2 MBIn this week’s episode, we will review a randomized phase 3 study of patients with high-risk peripheral T-cell lymphoma that compares results from autologous versus allogeneic stem cell transplant during consolidation, look at a report that examines the significance of ABO-incompatible platelet transfusion on outcomes after intracerebral hemorrhage, and learn about how immune dysregulation mediated by tumor interferon signaling and myeloid-derived suppressor cells is associated with ...
Season 2, Episode 18
May 06, 2021 16:30 - 19 minutes - 17.9 MBIn this week’s episode, we will review a prospective study suggesting that eculizumab discontinuation based on complement genetics is a reasonable and safe strategy in patients with atypical hemolytic uremic syndrome, examine a study that provides new insights into resistance mechanisms and immune evasion in T-cell acute lymphoblastic leukemia, and finally look at a research article describing a new disorder associated with variants in the TLR8 gene that is characterized by neutropen...
Season 2, Episode 17
April 29, 2021 16:30 - 18 minutes - 17.3 MBIn this week’s episode, we will review a study that focuses on the morphologic alterations of stored red blood cells, learn more about how T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis, and, finally, look at a report that describes how the WNT signaling pathway is involved in sclerodermatous chronic graft-versus-host disease and can be blocked by available therapeutics.
Season 2, Episode 16
April 22, 2021 16:30 - 20 minutes - 18.6 MBIn this week’s episode, we consider the role of MYC and BCL2 copy number variants in double-hit diffuse large B-cell lymphoma, explore megakaryocyte-biased stem cells in JAK2-mutated myeloproliferative neoplasms, and finally, we look at long-term outcomes with emicizumab prophylaxis in patients with hemophilia, which are even better than in the first reports.
Season 2, Episode 15
April 15, 2021 16:30 - 17 minutes - 16.4 MBIn this week’s episode, we will review a manuscript that describes a novel inherited bone marrow failure syndrome associated with defective clearance of formaldehyde by hematopoietic stem cells, learn about the first large scale analysis of the association between cancer-specific mutations in cancer cells and the incidence of cancer-specific thrombosis, and explore results from a large screening study examining the incidence and progression of monoclonal B cell lymphocytosis in famil...
Season 2, Episode 14
April 08, 2021 16:30 - 18 minutes - 17.3 MBIn this week’s episode, we discuss recent studies providing new insights on the use of minimal residual disease measurements to guide treatment in patients with high-risk ALL; the increasing risk of venous thromboembolism among patients with cancer; and the use of tocilizumab in the prophylaxis of acute graft versus host disease.
Season 2, Episode 13
April 01, 2021 16:30 - 18 minutes - 16.7 MBIn this week’s episode, we will learn more about the feasibility of combining IDH inhibitors with intensive chemotherapy in patients with newly diagnosed IDH-mutant AML, review a phenotypic and functional analysis of the inflammatory infiltrate in the Langerhans Cell Histiocytosis lesion, and discuss the results of a Phase 3 trial in patients with hemophilia A evaluating prophylactic factor replacement therapy targeting two different Factor VIII trough levels for prevention of bleeds...
Season 2, Episode 12
March 25, 2021 16:00 - 19 minutes - 18 MBIn this week’s episode, we look at the role of a previously unidentified variant of DNA methyltransferase 1 as a determinant of beta-thalessemia phenotype, report on the association of vascular thromboembolism in cancer patients treated with immune checkpoint inhibitors, and finally we explore preclinical models of acute erythroid leukemia using CRISPR/Cas 9 hematopoietic genome editing.
Season 2, Episode 11
March 18, 2021 16:00 - 19 minutes - 17.7 MBIn this week’s episode, will review a study that looks at primary diffuse large B-cell lymphoma of the central nervous system comparing tumor biologic features associated with Epstein-Barr virus, examine the functions of regulatory T cells in thrombus resolution in a mouse model, and learn more about subsequent malignant neoplasms in treated pediatric patients with Hodgkin lymphoma.
Season 2, Bonus: How I Treat Series: Acquired Hemolytic Anemia
March 15, 2021 16:11 - 19 minutes - 27.6 MBDiagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.
Season 2, Bonus: Platelets and Cancer
March 11, 2021 17:01 - 35 minutes - 32.5 MBDiagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.
Season 2, Episode 10
March 11, 2021 17:00 - 17 minutes - 15.9 MBIn this week’s episode, we will review recent studies providing new insights on frontline use of checkpoint inhibitors in classical Hodgkin lymphoma, immune escape mechanisms in diffuse large B-cell lymphoma, and the role of SRP54 mutations in congenital neutropenia.
Season 2, Episode 9
March 04, 2021 17:15 - 15 minutes - 14.4 MBIn this week’s episode, we will review a study that provides further evidence of poor prognosis in patients with multiple myeloma who have “double hit” mutations targeting TP53, examine the early use of BCR-ABL1 kinetics to predict the likelihood of treatment free remission in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors, and learn more about a direct causative link between IL-18 with arrythmias and myocardial fibrosis in sickle cell cardiomyopathy. ...
Season 2, Episode 8
February 25, 2021 17:00 - 18 minutes - 17.4 MBIn this week’s episode, we will learn more about pre-clinical work that aims to identify optimal immunotargets for treatment of pediatric AML, report on a novel path for subcutaneous administration of Factor 8, and highlight the performance characteristics of the platelet factor 4-dependent p-selectin expression assay for the diagnosis of heparin-induced thrombocytopenia.
Season 2, Episode 7
February 18, 2021 17:00 - 17 minutes - 16 MBIn this week’s episode, we will learn about the cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura, review outcomes of a phase 2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease, and examine results of a phase 1/2 study looking at the use of ibrutinib and obinutuzimab plus venetoclax in patients with mantle-cell lymphoma.
Season 2, Episode 6
February 11, 2021 17:30 - 16 minutes - 23.1 MBIn this week’s episode, we will cover recent research that provides new insights into the treatment of relapsed or refractory acute myeloid leukemia, immune-mediated thrombotic thrombocytopenic purpura, and sickle cell disease.
Season 2, Episode 5
February 04, 2021 17:00 - 18 minutes - 16.6 MBIn this week’s episode, we will review a study that describes the pathogenic relevance of retinoic acid-responsive CD8+ T-cells in gastrointestinal graft-versus-host disease, learn more about how storage-induced disturbances of platelets is linked to changes in the number and sphingolipid content of platelet extracellular vesicles which predispose to transfusion related acute lung injury, and lastly, review the findings of a phase II study of venetoclax plus R-CHOP as first-line trea...
Season 2, Episode 4
January 28, 2021 17:00 - 20 minutes - 18.4 MBIn this week’s episode, we will explore the characteristics of the tumor and immune environment as predictors of response to blinatumomab in B cell ALL, look at a new predictive tool for guiding decision-making for stem cell transplantation in acute myeloid leukemia, and review the mechanisms of how persistent terminal complement activation can still occur even in the presence of complement inhibitors targeting C3 or C5.
Season 2, Episode 3
January 21, 2021 17:00 - 14 minutes - 19.9 MBIn this week’s episode, we will review a study that shows neutrophils are required for optimum recovery from acute lung injury in a murine model, examine the implication of germline genetic factors in the myeloproliferative neoplasm, polycythemia vera, and learn about the use of emicizumab for bleeding control in a small study of patients with acquired hemophilia A.